Uncontrolled Clinical Trial of Quality- and Quantity-Cultured Peripheral Blood Mononuclear Cell Treatment for Androgenic Alopecia

This study evaluated the safety and efficacy of autologous MNC-QQ cell therapy for androgenic alopecia in a single-arm, open-label clinical trial involving 5 male patients. The treatment involved subcutaneous injections of 1×10^7 MNC-QQ cells into affected scalp areas, with follow-ups at 2 weeks, 1, 3, and 6 months post-injection. No adverse effects were reported. Three patients showed improvement in the Hamilton-Norwood stage, while the other two exhibited mild hair growth enhancement. At 6 months, significant increases were observed in total hair count, hair density, hair mass, mean hair thickness, and terminal hair density. All patients experienced improvements in quality of life, suggesting MNC-QQ cells as a promising alternative therapy for androgenic alopecia.